BELLUS Health Stock Forecast, Price & News

BELLUS Health (NASDAQ:BLU) Frequently Asked Questions

Is BELLUS Health a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BELLUS Health stock.
View analyst ratings for BELLUS Health or view top-rated stocks.

What stocks does MarketBeat like better than BELLUS Health?

Wall Street analysts have given BELLUS Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BELLUS Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BELLUS Health?

BELLUS Health saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 694,200 shares, a drop of 39.1% from the August 15th total of 1,140,000 shares. Based on an average daily trading volume, of 460,500 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.1% of the company's stock are sold short.
View BELLUS Health's Short Interest.

When is BELLUS Health's next earnings date?

BELLUS Health is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for BELLUS Health.

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) issued its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.03. BELLUS Health had a negative trailing twelve-month return on equity of 36.47% and a negative net margin of 311,879.97%.
View BELLUS Health's earnings history.

How has BELLUS Health's stock price been impacted by Coronavirus?

BELLUS Health's stock was trading at $9.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLU stock has decreased by 32.2% and is now trading at $6.37.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for BLU?

6 analysts have issued 12-month price objectives for BELLUS Health's shares. Their forecasts range from $8.00 to $14.00. On average, they expect BELLUS Health's stock price to reach $11.75 in the next year. This suggests a possible upside of 84.5% from the stock's current price.
View analysts' price targets for BELLUS Health or view top-rated stocks among Wall Street analysts.

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the following people:

• Roberto Bellini, President, Chief Executive Officer & Director
• Ramzi Benamar, Chief Financial Officer
• Catherine M. Bonuccelli, Chief Medical Officer
• Denis Garceau, Senior Vice President-Drug Development
• François Desjardins, Vice President-Finance

Who are some of BELLUS Health's key competitors?

Some companies that are related to BELLUS Health include Organogenesis (ORGO), Xencor (XNCR), ADC Therapeutics (ADCT), Deciphera Pharmaceuticals (DCPH), Trillium Therapeutics (TRIL), NGM Biopharmaceuticals (NGM), IVERIC bio (ISEE), Centessa Pharmaceuticals (CNTA), MorphoSys (MOR), Dicerna Pharmaceuticals (DRNA), Prelude Therapeutics (PRLD), Amneal Pharmaceuticals (AMRX), Global Blood Therapeutics (GBT), Aerpio Pharmaceuticals (ARPO) and uniQure (QURE).
View all of BLU's competitors.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), (IPOC), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

What is BELLUS Health's stock symbol?

BELLUS Health trades on the NASDAQ under the ticker symbol "BLU."

Who are BELLUS Health's major shareholders?

BELLUS Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (5.92%), Laurion Capital Management LP (3.85%), Citadel Advisors LLC (2.95%), Altium Capital Management LP (2.28%), Ikarian Capital LLC (1.29%) and Millennium Management LLC (0.94%).

Which major investors are selling BELLUS Health stock?

BLU stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Bank of Montreal Can, and Tri Locum Partners LP.

Which major investors are buying BELLUS Health stock?

BLU stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Millennium Management LLC, Ikarian Capital LLC, Altium Capital Management LP, Morgan Stanley, Morgan Stanley, Rockefeller Capital Management L.P., and Laurion Capital Management LP.

How do I buy shares of BELLUS Health?

Shares of BLU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately $6.37.

How much money does BELLUS Health make?

BELLUS Health has a market capitalization of $499.01 million and generates $10,000.00 in revenue each year. The company earns $-31,760,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does BELLUS Health have?

BELLUS Health employs 32 workers across the globe.

What is BELLUS Health's official website?

The official website for BELLUS Health is www.bellushealth.com.

Where are BELLUS Health's headquarters?

BELLUS Health is headquartered at 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The company can be reached via phone at (450) 680-4500 or via email at [email protected].